NCT04783935

Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)

A 2-year Extension Study to Evaluate Long-term Effectiveness of Mavenclad® in Participants Who Have Completed Trial MS700568_0022 (MAGNIFY MS) (Magnify MS Extension)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 219 (actual)
• Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary purpose of this study was to evaluate the long-term effectiveness of Mavenclad® tablets, in terms of disease activity and safety, in participants with highly-active relapsing multiple sclerosis (RMS) previously participating in the MAGNIFY MS trial MS700568\_0022 (NCT03364036).

Conditions

• Multiple Sclerosis

Interventions

Type	Name	Description
DRUG	Mavenclad®	No intervention was administered as a part of this study. Participants who had received Mavenclad® up to 2 years (Year 1 and 2) in the parent study MS700568\_0022 (NCT03364036) were enrolled into this extension study and will be assessed up to 2 years follow-up (Year 3 and 4).

Timeline

• Start date: 2021-03-10
• Primary completion: 2023-09-21
• Completion: 2023-09-21
• First posted: 2021-03-05
• Last updated: 2025-01-22
• Results posted: 2025-01-22

Locations

46 sites across 14 countries: Australia, Austria, Canada, Czechia, Finland, France, Germany, Hungary, Israel, Italy, Poland, Spain, Sweden, United Kingdom